Phibro acquires Zoetis' medicated feed additives, expanding global animal health and nutrition portfolio.
Read more
Ajax Therapeutics doses first patient in Phase 1 trial of AJ1-11095 for Myelofibrosis treatment.
Read more
Fertilitywise partners with Fertility and Surrogacy Legal Group to enhance legal support for fertility patients.
Read more
Chiauranib approved for Phase III trial in first-line treatment of extensive disease small cell lung cancer.
Read more
FELIQS' FLQ-101 receives FDA Fast Track for Retinopathy of Prematurity prevention.
Read more
Oncoinvent's Radspherin® shows promising safety and efficacy in Phase 1/2a study for Colorectal Cancer with peritoneal metastases.
Read more
Kelun-Biotech's sac-TMT receives third NDA acceptance for EGFR-mutant NSCLC by China's NMPA.
Read more
Tempus and Northwestern Medicine collaborate to apply AI in clinical care, starting with cardiovascular disease risk assessment.
Read more
Jackson Hospital partners with Medline for enhanced environmental services and operational efficiency.
Read more
Axonis Therapeutics secures $115M to advance KCC2-targeting therapies for Epilepsy and Pain.
Read more
Memo Therapeutics completes Phase II trial enrollment for potravitug in BK Viremia treatment for kidney transplant patients.
Read more
SUPLEXA shows promise in retraining immune cells for advanced Colorectal and Renal Cell Carcinoma treatment.
Read more
HanAll Biopharma reports Q3 2024 revenue growth and updates on Parkinson's Disease and autoimmune disease trials.
Read more
Aldeyra Therapeutics to present ADX-2191 Phase 2/3 trial results for Retinitis Pigmentosa at OSN New York Retina 2024.
Read more
Diadem's p53-specific antibody shows promise for early Alzheimer's Disease detection at CTAD 2024.
Read more
Anika Therapeutics sells Arthrosurface and plans to divest Parcus Medical to focus on Osteoarthritis Pain Management and Regenerative Solutions.
Read more
SUPLEXA shows promise in retraining immune cells for advanced Colorectal and Renal Cell Carcinoma, with FDA backing for Phase 2 trials.
Read more
MHRA approves CStone's sugemalimab for first-line treatment of metastatic Non-Small Cell Lung Cancer in the UK.
Read more
Verastem submits NDA to FDA for avutometinib and defactinib in recurrent KRAS mutant low-grade serous ovarian cancer.
Read more
ALX Oncology's evorpacept shows promise in Phase 1b/2 trial for HER2-positive metastatic breast cancer.
Read more
Teva's TEV-'749 shows improved social functioning in schizophrenia patients in Phase 3 SOLARIS trial.
Read more
Semaglutide 2.4 mg shows significant improvement in liver fibrosis and MASH resolution in Phase III ESSENCE trial.
Read more
3X4 Genetics partners with Rupa Health to enhance personalized care through genetic insights.
Read more
Werewolf Therapeutics introduces WTX-921, a novel IL-10 INDUKINE molecule for Inflammatory Bowel Disease treatment.
Read more
Sutro Biopharma initiates trial for Luvelta in pediatric patients with CBF/GLIS Acute Myeloid Leukemia.
Read more
